Form 4: Oncocyte Corp Executive James Liu Reports Stock Option and Restricted Stock Unit Grant

James Liu, VP, ACCT, Cntlr, Treasurer, and PAO of Oncocyte Corp, reports the acquisition of stock options and restricted stock units.

Summary

• On March 26, 2025, James Liu, VP, ACCT, Cntlr, Treasurer, and PAO of Oncocyte Corp, reported the acquisition of 10,000 options to purchase common stock at an exercise price of $3.18.
• These options vest over three years, with one-third becoming exercisable after one year and the remainder vesting in 24 equal monthly installments thereafter.
• Liu also acquired 18,867 restricted stock units (RSUs) that vest in three equal annual installments starting on the first anniversary of the grant date.
• Following these transactions, Liu directly owns 10,000 derivative securities and 18,867 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock option and RSU grants, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock options and restricted stock units granted to a company executive, which is a common practice for incentivizing and retaining key personnel in publicly traded companies.

Stakeholder Impact

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates

Keywords

Form 4, Oncocyte Corp, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading